8-K
filed May 4, 2026, 7:59 PM ET
ticker GYRE
CIK 0001124105
M&A
confidence high
sentiment positive
materiality 0.85
GYRE THERAPEUTICS, INC. (GYRE): M&A transaction — Gyre Therapeutics completes $300M all-stock acquisition of Cullgen; appoints Ying Luo as CEO
GYRE THERAPEUTICS, INC.
- All-stock deal valued at ~$300M closed; Cullgen becomes wholly owned subsidiary.
- Ying Luo appointed CEO and President; Ping Zhang remains Chairman.
- Combined company has commercial ETUARY® in China for lung fibrosis and late-stage pipeline including F351 for liver fibrosis.
- Cullgen contributes targeted protein degrader (TPD) and degrader-antibody conjugate (DAC) pipeline.
- Company will hold stockholder meeting June 10, 2026 for approval of conversion of Series B Preferred to common.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ying Luo was appointed as Chief Executive Officer, President, Director at GYRE THERAPEUTICS, INC..
- Action
- appointed
- Role
- Chief Executive Officer, President, Director
Exact text from the filing
effective immediately after the Effective Time, the Company appointed Ying Luo, Ph.D. as Chief Executive Officer and President of the Company and to the Board as a Class I director.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Songjiang Ma resigned as Director, President at GYRE THERAPEUTICS, INC..
- Action
- resigned
- Role
- Director, President
Exact text from the filing
Thomas Eastling and Songjiang Ma resigned from the board of directors of the Company (the "Board") and any respective committee of the Board to which they were members, and Mr. Ma also resigned from his position as President of the Company on such date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ruoyu Chen resigned as Chief Financial Officer at GYRE THERAPEUTICS, INC..
- Action
- resigned
- Role
- Chief Financial Officer
Exact text from the filing
Ruoyu Chen, who resigned from her position as Chief Financial Officer on such date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Thomas Eastling resigned as Director and Member of Committees at GYRE THERAPEUTICS, INC..
- Action
- resigned
- Role
- Director and Member of Committees
Exact text from the filing
Thomas Eastling and Songjiang Ma resigned from the board of directors of the Company (the "Board") and any respective committee of the Board to which they were members
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Thomas Eastling was appointed as Chief Financial Officer at GYRE THERAPEUTICS, INC..
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
the Company appointed Thomas Eastling as Chief Financial Officer of the Company, to succeed Ruoyu Chen, who resigned from her position as Chief Financial Officer on such date.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
GYRE THERAPEUTICS, INC.: Filed a Certificate of Designation creating a new series of preferred stock in connection with a merger.
- Change
- charter amendment
Exact text from the filing
The Company has filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Company Preferred Stock (the “Certificate of Designation”) in connection with the Merger referenced in Item 1.01 above.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
GYRE THERAPEUTICS, INC. completed an acquisition involving Cullgen Inc. for all-stock transaction that valued Cullgen at approximately $300 million (closed 2026-05-04).
- Action
- acquisition
- Counterparty
- Cullgen Inc.
- Consideration
- all-stock transaction that valued Cullgen at approximately $300 million
- Closing
- 2026-05-04
Exact text from the filing
Revenue Code of 1986, as amended. Under the terms of the Merger Agreement, the Company acquired Cullgen in an all-stock transaction that valued Cullgen at approximately $300 million. At the effective time of the Merger (the “Effective Time”), each then outstanding share of Cullgen capital stock (the “Cullgen Capital Stock”), excluding shares of Cullgen
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.